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Abstract
Young people living with perinatally acquired HIV may be at risk of poor adherence to antiretroviral therapy; identification of predictors,
using a conceptual framework approach proposed previously by others, is important to identify those at higher risk. In 261 young people
with perinatally acquired HIV in England, 70 (27%) reported 3-day nonadherence, 82 (31%) last month nonadherence, and 106 (41%)
nonadherence on either measure. Of those reporting nonadherence on both measures, 52% (23/44) had viral load of,50 copies/ml,
compared with 88% (127/145) of those reported being fully adherent. In multivariable analysis, young person and medication theme
factorswereassociatedwithnonadherence.Themainpredictorsof3-daynonadherencewereantiretroviral therapycontainingaboosted
protease inhibitor and poorer quality of life. Predictors of lastmonth nonadherencewere having toldmore people about one’s HIV status,
worse self-perception about having HIV, and boosted protease inhibitor–based regimens. The consistency of individual young person
and medication factors in predicting nonadherence gives insight into where interventions may best be targeted to improve adherence.
Keywords: adherence, adolescents and young adults, conceptual framework, HIV, perinatal, young people
Young people (adolescents and young adults ages10–24 years) living with perinatally acquired HIV
(PHIV) may be at particular risk of poor antiretroviral
adherence due to several factors. First, across many
chronic conditions requiring long-term treatment, main-
tenance of medication adherence can be problematic
(Patton et al., 2016). Advances in antiretroviral therapy
(ART) have led to simplified regimens and also single
tablet regimens, but the behavior required to adhere to
treatment is a challenge to sustain over time (Kacanek
et al., 2019). Second, the adolescent period can exacerbate
adherence challenges, at a time when responsibility for
disease management may transfer from the caregiver to
the young person (Anon, 2016). This period is charac-
terized by significant physiological and psychosocial
change, maturation of emotional development, and dy-
namic brain development, which all impact on short-term
and long-termgoal setting anddecision-makingprocesses,
which in turn may affect adherence (Patton et al., 2016).
Studies show thatmedication adherence generally declines
as children with chronic conditions enter adolescence
(Penazzato et al., 2018; Virella Perez et al., 2019). Third,
the context of perinatal HIV may generate its own issues,
including secrecy about HIVwithin the family and stigma
(Kawuma-Kagawa et al., 2014). Also, people living with
PHIV may have more difficulties adhering to ART than
peers living with nonperinatal HIV, due to having lived
with HIV for a longer period (MacDonell et al., 2013).
They may have more complex ART treatment regimens
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and may have experienced the death of parent(s) early in
life, andhaveanxietyarounddisclosing theirHIVstatus to
others (Xu et al., 2017).
Poor ART adherence compromises virological sup-
pression and increases the risk of developing HIV drug
resistance, disease progression, and transmission of the
virus to others (Ammon et al., 2018; Hudelson & Cluver,
2015). Thus, ongoing monitoring of ART adherence and
identification of predictors is important to identify those at
higher risk for ART nonadherence. However, few large
studies to date have focussed specifically on PHIV or have
been able to capture the diverse range of predictors that
have shown tobe associatedwithARTadherence inyoung
people, including medication-related, patient-related,
family-related, and psychosocial predictors (Adejumo
et al., 2015;Altice et al., 2019;Enaneet al., 2018;Evangeli,
2018; Hudelson & Cluver, 2015; Kim et al., 2014).
A conceptual framework for the wide range of factors
associated with ART adherence has been proposed by
Haberer andMellins (2009). This conceptual framework
was used in a systematic review of adherence to ART
therapy in adolescents living with HIV (Hudelson &
Cluver, 2015), incorporating four key themes influencing
adherence: adolescent, caregiver, medication (including
caregiver vs. youngperson administration anddisclosure,
due to their associations with medication nonadherence),
and social and physical environment. Although the re-
viewwasunable to identify factors consistently associated
with nonadherence across the studies included, using the
conceptual framework, the authors were able to detect
important themes such as gender, knowledge of HIV di-
agnosis, family structure, type of ART regimen, attitudes
about medication, geographical location, and having
missed clinic appointments (Hudelson & Cluver, 2015).
Therefore, this framework provides an evidence-based
model that can help clinicians conceptualize the complex
interplay between factors influencing ART adherence
across heterogeneous populations globally.
In this study, we explore the prevalence of ART non-
adherence in all young people living with HIV partici-
pating in the Adolescents and Adults Living with
Perinatal HIV (AALPHI) cohort. We used the concep-
tual framework approach, by grouping potential pre-
dictors of nonadherence into four themes, to explore the
association betweenART adherence and awide range of
factors collected in the AALPHI cohort.
Methods
Adolescents and Adults Living with Perinatal HIV is
a prospective study evaluating the impact ofHIV infection
and ART exposure on PHIV in England and comparing
outcomes with HIV-uninfected young people, across
multiple areas of inquiry, including cognitive function
(Judd et al., 2016); cardiac function, anxiety, and de-
pression (Le Prevost et al., 2018); sexual and reproductive
health (Judd et al., 2018); and self-harm (Copelyn et al.,
2019). This analysis includes only young people in AAL-
PHIwith PHIV.Three hundred sixteen youngpeoplewith
PHIV, ages 13–21 years, were recruited into the AALPHI
study between 2013 and 2015; these participants were
also in thenationwideU.K.and IrelandCollaborativeHIV
Paediatric Study (CHIPS; Collins et al., 2017). The young
people recruited were broadly representative of young
people with PHIV in the United Kingdom and Ireland
(Judd et al., 2016). All young people meeting the study
inclusion criteria were approached in 18 HIV clinics and
four community service locations in England, and volun-
tarily provided informed consent. Young people younger
than 18 years were allowed to consent to participation in
the study themselves if they were deemed by the study
research nurses as having the capacity to consent. This
involved study research nurses having discussions with
clinicians and/or voluntary sector staff about the young
person’s physical and emotional state and their capacity to
consent, before the young person being approached to
participate in the study. Furthermore, to ensure young
people had adequate information to decide whether to
participate in the study, research nurses read the patient
information sheet to the young person and answered any
queries. In addition, all the points in the consent formwere
discussed and questions posed throughout the consent
process to help the research nurse decide if the young
person had the ability and maturity to consent to partici-
pating in the study. Participants provided written in-
formed consent, except where they lacked the capacity, in
which case parents or guardians provided written in-
formed consent and the young person provided written
assent. Full ethical approval was granted from Leicester
Research Ethics Committee. The sample size for the study
was based on power to detect comparisons between the
PHIV and HIV-uninfected groups, and no specific power
calculations were undertaken to detect differences within
the PHIV group only.
Participantsunderwenta2-hour face-to-face interview,
with a trained researchnurse,which includeda computer-
assisted self-interviewing section where data were col-
lected on ART adherence. The two adherence measures
assessed medication taking behavior—missing any doses
in the last 3 days (“3 day nonadherence”) and also having
missed more than 2 days’ of doses in a row in the last
month (“last month nonadherence”), which have been
used in previous studies (Harrison et al., 2013). Although
these specificmeasures have not been validated against an
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external reference, similarquestions (e.g.,missingdoses in
the last 2 days, and number of days in last month not
taking drugs as prescribed) have been validated and/or
correlated with viral load (VL; Scott et al., 2018).
Respondents also reported whether any doses were par-
ticularly hard to take, reminders that were used, and
reasons for nonadherence. VL and CD41 T-cell data
closest to the AALPHI interview date (66 months) were
extracted from routine laboratory tests collected in CHIPS.
This analysis differs from other publications from
AALPHI because it takes a quantitative approach to
assessing ART adherence and its predictors in all PHIV
inAALPHI. A previous publication onART adherence in
a small subset (29 participants) of the PHIV group in
AALPHI looked at young people who took their medi-
cation inconsistently (i.e., periods of adherence and non-
adherence in the same participant; Hawkins et al., 2016).
Therefore, the analysis of the adherence data from all the
young people with PHIV in the cohort in this article is
appropriate because of the lack of studies to date in-
vestigating adherence in young people with PHIV, which
have a large sample size and with a wide range of data
collected on potential predictors.
Data Analysis
Participants were included in the analysis if they had
completed the adherence questionnaire in the main in-
terview, as described above. These participants may have
been included in the analysis in previous publications
from this cohort; however, the data collected specifically
on adherence, which is the focus of this article, have not
been analyzed or reported previously. The effects of po-
tential predictors on 3-day and last month nonadherence
were explored using logistic regression. Potential pre-
dictors of nonadherence were grouped into four concep-
tual framework themes, based on previous studies
(Haberer & Mellins, 2009; Hudelson & Cluver, 2015).
All instruments used in the study are described in Table 1.
Young person–related factors included sex, age at in-
terview, ethnicity, and being born outside the United
Kingdom,whichwere considered a priori to be associated
with both 3-day and last month nonadherence. Other
young person–related factorswere cognitive function (six-
domain summary neuropsychological z score [NPZ-6],
calculated as the mean z score across six cognitive
domains; Judd et al., 2016) and mental health measures,
including anxiety and depression symptoms (Hospital
Anxiety andDepression Scale; Zigmond&Snaith, 1983),
health-related quality of life (Pediatric Quality of Life In-
ventory 4.0; Varni, 2012; Varni et al., 1999), self-esteem
(Rosenberg Self-esteem Scale; Rosenberg, 1965), and self-
perception about having HIV (composite score of level of
upset, worry, sadness, loneliness, and concern about fu-
ture health; developed by the authors).
Caregiver-related factors were death of one or both
parents, whether fostered or adopted, number of main
caregivers (different adults taking responsibility for and
living with the participant during childhood), and main
language spoken at home.
Medication-related factors were age at ART start,
Centers for Disease Control and Prevention stage, di-
agnosis of encephalopathy (as reported by the clinic to
the CHIPS study), years taking ART, total number of
tablets taken per day, frequency of takingART each day,
class of ART regimen, and having transferred to adult
care. Other medication-related factors were the number
of people whom the young people had told about their
HIV, number of people they were able to talk to about
theirHIV, andwhether everyone in the family homewas
aware of their HIV status, which were all self-reported
by the young person.
Social- and physical-related factors were residential
deprivation score (Income Deprivation Affecting Chil-
dren Index; Department for Communities and Local
Government, 2015), current education/employment sta-
tus, and whether living with parents. These predictors
have been used in previous publications from this cohort,
although have not previously been grouped into themes.
Results are presented for nonmissing values; missing
values were less than 10% of study participants unless
specified. Variables attaining a p value of ,.1 in uni-
variable logistic regression analyses were considered in
multivariable analysis using backward selection, as well
as the a priori variables (sex, age at interview, ethnicity,
and being born outside the United Kingdom), and a two-
tailed p value of,.05 was considered statistically signif-
icant (Bursac et al., 2008). A similar analysis approach
has been used in previous publications from this cohort,
albeitwithdifferent outcomevariables.Years takingART
and total number of tablets taken per day were not con-
sidered inmultivariable analysis because theywere highly
correlatedwith class ofART regimenand excludeddue to
collinearity concerns (Armitage, Berry, & Matthews,
2002). Data were analyzed using STATA version 15
(Stata Corp, College Station, TX).
Results
A total of 261 PHIVyoung people takingARTanswered
questions on ART adherence. Of these, 238 (91%) were
on once-daily regimens, of whom 131 (55%) were tak-
ing ART combinations containing boosted protease
inhibitors (PI) and 98 (41%) were taking nonnucleoside
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reverse transcriptase inhibitor (NNRTI)–based regi-
mens. Of the 23 young people on twice-daily regimens,
18 (78%) and 2 (9%)were taking PI- andNNRTI-based
regimens, respectively.
Of the 261 total participants, the median age was 16
years (interquartile range, 15–18), 112 (43%)were male,
85% Black African, 59% born outside of the United
Kingdom, and themajority studying and livingwith their
parents (Table 2). At the time of the interview, 78% had
aVLof,50copies/ml,mediumCD4countwas 629 cells/
mm3 (interquartile range, 465–814), and 61 (23%) had
already transitioned from pediatric to adult care.
One quarter (n 5 69/251, 27%) reported problems
taking weekday doses, 98 of 252 (39%) weekend doses,
and 50 of 251 (20%) both weekday and weekend doses.
Half (n5 147, 56%) used reminders to help adherence,
including family members (107/147, 73%), pill boxes
(20%), timers (20%), daily routines (e.g., breakfast time;
10%), text messages (7%), and friends (7%).
Twenty participants (8%) reportedmissing doses on the
day of the interview, 30 (11%) the preceding day, and 53
(20%) the day before that, with a total of 70 (27%)
reporting 3-day nonadherence. One third (n 5 82, 31%)
reported last month nonadherence, and 41% (106/261)
reported nonadherence on eithermeasure.Of those taking
ART once daily, 94 of 238 (40%) reported nonadherence
on either measure compared with 12 of 23 (52%) taking
ART twice daily, and a higher proportion of young people
on boosted PI-based regimens (68/149, 46%) reported
nonadherence on either measure compared with those on
NNRTI-based regimens (29/100, 29%). Themain reasons
for missing ART doses were forgetting (72/106, 68%),
being away from home (37%), being asleep at the time the
dose should be taken (30%), feeling too tired (29%), not
being able to deal with ART that day (24%), not wanting
others to know (23%), school hours interfering with ad-
herence (23%), and running out of ART drugs (15%),
with no difference in the reasons given by daily frequency
or class of ART regimen (data not shown).
Of those reporting 3-day and lastmonth nonadherence,
only 52% (23/44) had a suppressed VL of,50 copies/ml,
compared with 70% (16/23) for those reporting 3-day
nonadherence only, 77% (27/35) for those reporting last
month nonadherence only, and 88% (127/145) for those
reporting adherence on both measures. There was no
difference in VL suppression by daily frequency of ART
(data not shown); however, a lower proportion of young
people had suppressed VL if they were taking boosted PI-
based regimens (95/141, 67%) compared with NNRTI-
based regimens (91/96, 95%; p, .001).
In univariable analysis (Table 3), only young person
(Hospital Anxiety and Depression Scale depression score,
PedsQL, Rosenberg Self-esteem Scale, HIV self-
perception) and medication (years taking ART, total
number of tablets taken per day, ART class, number of
people told aboutHIV) theme factors, andnot caregiveror
social- andphysical-related factors,wereassociatedwith3-
day nonadherence (p , .1). After adjustment for a priori
variables (sex, age at interview, ethnicity, and being born
outside the United Kingdom), those with poorer quality of
life (adjusted odds ratio [aOR], 2.39 per 25 units worse;
95% confidence interval [CI], 1.31–4.36; p 5 .004), and
Table 1. Instruments Used in the Study
Theme Instrument/Measure Scoring
Young person NPZ-6 Mean z-score across 6 domains, documented previously (Judd
et al., 2016)
HADS Scores range from 0 to 21, with higher scores indicating more
severe anxiety or depression (Zigmond & Snaith, 1983)
PedsQL Teenage report for 13–18 years and young adult report for
18–25 years; scores range from 0 to 100 and a higher score
indicates better social functioning (Varni, 2012; Varni et al.,
1999)
Rosenberg SES Scores range from 0 to 30: higher scores indicate better self-
esteem (Rosenberg, 1965)
Social and physical IDACI Scores range from 0 to 1; a higher score indicates more severe
deprivation (Department for Communities and Local
Government, 2015)
Note. HADS5Hospital Anxiety andDepressionScale; IDACI5 IncomeDeprivationAffectingChildren Index;NPZ5Neuropsychological
z Score; PedsQL5 Pediatric Quality of Life Inventory; SES5 Self-esteem Scale.
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Table 2. Young Person, Caregiver, Medication, and Social and Physical Characteristics of Young People
With PHIV Taking ART (n 5 261)
Theme Variable Category N (%) or Median [IQR]
Young person Sex Male 112 (43%)
Age (years) 16 [15 to 18]
Ethnicity Black 221 (85%)
Born outside of UK 153 (59%)
NPZ-6a 20.5 [21.0 to 0.1]
HADS anxietyb 6 [3 to 9]
HADS depressionb 3 [1 to 6]
PedsQLc 77 [67 to 87]
Rosenberg SESd 21 [17 to 25]
Self-perception about HIVe 35 [22 to 44]
Caregiver Death of one/both parents 87 (35%)
Fostered/adoptedf 14 (13%)
Number of main carers 1 [1 to 2]
Main language spoken at home English only 136 (52%)
Medication Age at ART start (years) 7 [3 to 11]
CDC stage at interview N/A/B 184 (70.5%)
C 77 (29.5%)
Ever HIV encephalopathy 9 (3%)
Years taking ART 9 [5 to 13]
No. tablets taken each day 1 38 (15%)
2 64 (25%)
$3 151 (60%)
Once daily regimen 238 (91%)
ART class NNRTI based 100 (39.5%)
Boosted PI based 149 (59%)
Other 4 (1.5%)
Transferred to adult care 61 (23%)
No. people young person has told
about their HIV
0 143 (56%)
1–2 62 (24%)
31 49 (19%)
No. people young person has spoken
to about HIV in last 12 months (family/
friends/ clinic)
0 94 (37%)
1-2 79 (31%)
31 81 (32%)
(continued on next page)
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those taking boosted PI-based ART combinations (aOR,
2.67; 95% CI, 1.34–5.30 vs. NNRTI-based; p 5 .005),
had higher odds of 3-day nonadherence.
In the model investigating predictors of last month
nonadherence (Table 4), again, only young person and
medication theme factors had an association.Worse self-
perception about having HIV (aOR, 1.17 per 5 unit
decrease; 95% CI, 1.06–1.30; p 5 .003), having told
more people about their HIV status (1–2 persons aOR,
1.49; 95% CI, 0.72–3.10;$3 persons aOR, 3.29; 95%
CI, 1.53–7.08vs. none;p5 .009), and takingboostedPI-
based ART combinations (aOR, 2.25; 95% CI,
1.19–4.24 vs. NNRTI-based; p5 .013) were associated
with last month nonadherence.
Discussion
In this cohort of long-term survivors of perinatalHIV, two
of five reported missing any doses in the 3 days before the
study interview and/or missing more than 2 days of doses
in a row in the last month. Twenty-one participants (8%
of the total) reported missing doses on both of these ART
adherence measures and had unsuppressed VL at in-
terview.By far, themost commonreason formissingdoses
was forgetting. Overall, the prevalence of nonadherence
was in keeping with findings from other studies. A sys-
tematic review published in 2018 documented adherence
levels varying from 64% to 90%, although nonadherence
levels in the past week varied widely from 6% to 95%
(Ammon et al., 2018). An earlier review found adherence
in the 30 days before interview being 28% to 70%
(Reisner et al., 2009). However, both included all young
peoplewithHIV, andnot just thosewithPHIV,whichwas
the focus of this article. Larger, more recent primary re-
search studies included a study of 250 adolescents living
with (primarily perinatally acquired)HIV recruited across
three countries in Asia and followed them longitudinally
for 3 years. In this study, 60% to 69% of adolescents
reported adherence in the last month of #95% at the
various time points of follow-up (Ross et al., 2019). In
SouthAfrica, 70%of474adolescentswithPHIVreported
no missed doses in the last 30 days (Brittain et al., 2018).
More recent evidence from the United States highlights
how in young people with PHIV followed longitudinally,
around 40% reported missing an ART dose in the last
week, and the presence of psychiatric disorders was
strongly associatedwithmissed doses (Bucek et al., 2018).
Thishighlights howtargeted interventions in this areamay
help improve adherence in young people.
The conceptual framework used in our study was de-
veloped to facilitate understanding of the varied challenges
affecting adherence to ART among children and adoles-
cents across heterogeneous populations worldwide (Hab-
erer & Mellins, 2009). This model incorporates factors
beyond those affecting other young people with chronic
illnesses, by, for example, including caregiver character-
istics such as vitality status and awareness of HIV in
the home. Future studies might consider incorporating
Table 2. (continued)
Theme Variable Category N (%) or Median [IQR]
Everyone in family home knows status 165 (69%)
Social, physical IDACI scoreg 0.4 [0.3 to 0.5]
Occupation Education 242 (93%)
Employment 5 (2%)
Not in education/employment 12 (5%)
Live with parents 236 (91%)
Note. ART 5 antiretroviral therapy; CDC5 Centers for Disease Control and Prevention; HADS5 Hospital Anxiety and Depression
Scale; IDACI5 Income Deprivation Affecting Children Index; IQR5 interquartile range; PedsQL5 Pediatric Quality of Life Inventory;
SES5 Self-esteem Scale; NNRTI 5 nonnucleoside reverse transcriptase inhibitor; PHIV 5 perinatally acquired HIV; PI 5 protease
inhibitor; UK5 United Kingdom.
a Summary score calculated as the mean z-score across six cognitive domains.
b Scores range from 0 to 21; higher scores indicate more severe anxiety or depression.
cMean score over 23 questions, each question ranges from 0 to 100, and higher scores representing better health-related
quality of life.
d Scores range from 0 to 30, with higher scores indicating better self-esteem.
e Composite total score ranges from 0 to 50, and higher scores indicate better feelings about having HIV.
f Unknown for 151 as question was introduced part way through the study.
g Score ranges from 0 to 1, with higher score indicating more severe deprivation; unknown for 34.
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Table 3. Prevalence, and Univariable and Multivariable Predictors of Missing Any Doses of ART in the Last 3 Daysa
Variable (Theme) Categories
Missing ‡ 1 Dose
n/Total, % orM (SD)
Univariable Multivariable
Odds Ratio 95% CI p-Value Odds Ratio 95% CI p-Value
Sex (young person) Male 25/112, 22% 1.00 1.00 —
Female 45/149, 30% 1.51 0.86–2.65 .156 1.11 0.56–2.19 .761
Age (years) at interview (young
person)
M age, no missed dose 16.8 (2.3) — — — — —
M age, missed dose 17.1 (2.1) — — — — —
Per year increase — 1.06 0.94–1.20 .317 1.06 0.92–1.23 .384
Ethnicity (young person) Non-Blackb 7/40, 18% 1.00 1.00 —
Black 63/221, 29% 1.88 0.79–4.47 .153 2.37 0.89–6.31 .083
Country of birth (young person) United Kingdom 32/108, 30% 1.00 1.00 —
Outside of United
Kingdom
38/153, 25% 0.78 0.45–1.36 .390 0.77 0.41–1.45 .420
HADS depression score (young
person)
Normal/mild (,11) 61/232, 26% — — — — — —
Moderate/severe ($11) 4/11, 36% — — — — — —
Per unit worse — 1.08 0.99–1.18 .076 — — —
PedsQL (quality of life) (young
person)
M score, no missed dose 78.4 (13.2) — — — — — —
M score, missed dose 71.2 (13.6) — — — — — —
Per 25 unit worse — 2.62 1.55–4.44 ,.001 2.39 1.31–4.36 .004
Rosenberg SES (self-esteem)
(young person)
M score, no missed dose 21.2 (5.1) — — — — — —
M score, missed dose 20.0 (5.7) — — — — — —
Per 5 unit worse — 1.26 0.97–1.64 .089 — — —
HIV self-perception (young
person)
M score, no missed dose 33.1 (14.0) — — — — — —
M score, missed dose 26.9 (15.9) — — — — — —
Per 5 unit worse 1.15 1.05–1.26 .003 — — —
(continued on next page)
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Table 3. (continued)
Variable (Theme) Categories
Missing ‡ 1 Dose
n/Total, % orM (SD)
Univariable Multivariable
Odds Ratio 95% CI p-Value Odds Ratio 95% CI p-Value
Years taking ART (medication) M years, no missed dose 9.1 (4.9) — — — — — —
M years, missed dose 10.4 (4.6) — — — — — —
Per year increase 1.06 1.00–1.12 .061 — — —
Total number of tablets taken 1 5/38, 13% 1.00 — — —
per day (medication) $ 2 60/215, 28% 2.55 0.95–6.85 .062 — — —
ART class (medication) NNRTI based 16/100, 16% 1.00 1.00
Boosted PI based 47/149, 32% 2.42 1.28–4.57 .007 2.67 1.34–5.30 .005
No. people told about HIV
(medication)
None 31/143, 22% 1.00 — — —
1–2 19/62, 31% 1.60 0.82–3.12 — — —
$ 3 19/49, 39% 2.29 1.14–4.60 .056 — — —
Note. ART5 antiretroviral therapy; CI5 confidence interval; HADS5Hospital Anxiety and Depression Scale; NNRTI5 nonnucleoside reverse transcriptase inhibitor; PedsQL5
Pediatric Quality of Life Inventory; PI 5 protease inhibitor; SES 5 Self-esteem Scale.
a Factors attaining an univariable p value , .10, and a priori variables (sex, age at interview, born in United Kingdom vs. abroad, ethnicity) are shown in the table.
b Non-Black includes White, mixed, Asian, and Chinese. Black includes Black Caribbean, Black African, and other Black.
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Table 4. Prevalence, and Univariable and Multivariable Predictors of Missing More Than 2 Days of Doses in a Row in the Last Montha
Variable (Theme) Categories
Missing > 2 Days
n/Total, % orM (SD)
Univariable Multivariable
Odds Ratio 95% CI p-Value Odds Ratio 95% CI p-Value
Sex (young person) Male 32/112, 29% 1.00 1.00 —
Female 50/149, 34% 1.26 0.74–2.15 .391 1.13 0.61–2.09 .706
Age (years) at interview (young
person)
M age, no missed dose 16.8 (2.3) — — — — — —
M age, missed dose 17.1 (2.2) — — — — — —
Per year increase — 1.06 0.95–1.19 .303 0.97 0.84–1.11 .653
Ethnicity (young person) Non-Blackb 12/40, 30% 1.00 1.00 —
Black 70/221, 32% 1.08 0.52–2.25 .834 1.40 0.60–3.24 .437
Country of birth (young person) United Kingdom 40/108, 37% 1.00 1.00 —
Outside of United
Kingdom
42/153, 27% 0.64 0.38–1.09 .101 0.57 0.31–1.05 .070
HADS depression score (young
person)
Normal/mild (,11) 71/232, 31% — — — — — —
Moderate/severe ($11) 4/11, 36% — — — — — —
Per unit worse — 1.08 0.99–1.17 .087 — — —
PedsQL (quality of life) (young
person)
M score, no missed dose 78.3 (13.0) — — — — — —
M score, missed dose 72.3 (14.4) — — — — — —
Per 25 unit worse — 2.24 1.36–3.69 .002 — — —
Rosenberg SES (self-esteem)
(young person)
M score, no missed dose 21.3 (4.9) — — — — — —
M score, missed dose 20.0 (6.0) — — — — — —
Per 5 unit worse — 1.25 0.97–1.62 .083 — — —
HIV self-perception (young person) M score, no missed dose 33.4 (13.7) — — — — — —
M score, missed dose 27.1 (16.1) — — — — — —
Per 5 unit worse 1.15 1.05–1.26 .002 1.17 1.06–1.30 .003
(continued on next page)
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measurement of variables spanning the four framework
themes contributing to adherence, to disentangle the rela-
tive effects of each in contrasting populations.
In our analysis, young person andmedication themes
were the strongest predictors of nonadherence. Factors
associated with nonadherence in both outcome models
included poorer quality of life and worse self-perception
about having HIV, as well as having told more people
about their HIV status. Disclosure was also found to be
predictive of loss to follow-up in a study from South
Africa, which found that adults who had disclosed to
partners andwere open to family and friends about their
HIV status had higher levels of disengagement from care
(Evangeli et al., 2016). Thus, secrecy around HIV status
may be associated with better adherence and warrants
further investigation. Taking ART regimens containing
boosted PIs was a consistent predictor across both
models in our study; this likely reflects previous poor
adherence and subsequent switching to a PI-based regi-
men, which has a higher genetic barrier to drug re-
sistance (British HIV Association, 2016), the fact that
most twice daily regimens were boosted PI-based, or
suggest tolerability issues with PIs.
Three reviews to date have focused on predictors of
adherence in young people with HIV (Adejumo et al.,
2015; Hudelson & Cluver, 2015; Reisner et al., 2009).
Literature review of Reisner et al. (2009) from the United
States suggested that sociodemographics (age, sex, eth-
nicity) did not predict adherence, and in contrast, psy-
chosocial factors (such as HIV stigma and discrimination
by friends and family, lower levels of life satisfaction, de-
pression, and anxiety) were most consistently associated
with nonadherence across studies, similar to our study.
Adejumo et al. (2015) similarly highlighted the impor-
tance of psychological, socioeconomic, individual, and
treatment-related factors influencing adolescent adher-
ence in sub-Saharan Africa. Hudelson and Cluver (2015)
reviewed literature from low- and middle-income coun-
tries andnoted that therewere fewconsistent relationships
across studies between measured factors and adherence,
but important emerging themes included knowledge of
serostatus, the influence of family structure, the impact of
variousARTregimens, andhealth careandenvironmental
factors such as rural versus urban location and missed
clinic appointments (Hudelson & Cluver, 2015).
Our study has a number of limitations. First, it iswidely
recognized that there is no gold standard measure of ad-
herence. However, we did ask specific questions about
missing any doses in the last 3 days andmissingmore than
2 days in the last month; it is possible that other periods
of nonadherence were missed. To encourage truthful
reporting of ART adherence, we used computer-assistedT
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self-interviewing and stressed confidentiality and disas-
sociation of the study staff with medical staff treating
study participants. Furthermore, wording of the ART
adherence questionswas constructed in a nonjudgemental
way. The relatively short period of recall was specifically
selected in an attempt to minimize recall bias. Second,
althoughwe applied a conceptual framework approach to
variable grouping, we had fewer variables in some of the
themes, which may make them less likely to have a pre-
dictor associated with the outcome. Third, we did not
measure levels of felt stigma, preparedness to transition
from pediatric to adult HIV services, responsibility for
medication adherence, adherence motivation, behavioral
skills and self-efficacy, levels of drug resistance, or psy-
chiatric comorbidity, all of which could have been in-
formative. Fourth, our data were collected at the baseline
AALPHI interview, and so the temporal association be-
tween factors and adherence could not be ascertained.
Thus, for example, poorer quality of life could have been
a cause or a consequence of nonadherence.
In conclusion, two in five young people in our study
reported some level of ART nonadherence, and of those
having missed doses, one in 10 were virally unsuppressed
at interview. Predictors of nonadherence were related to
the individual young person and medication factors,
highlighting the importance of these domains and, in
particular, when thinking about transition to adult care.
They give insight into where to focus additional resources
on supporting young people with PHIV in England to
improve adherence and virological suppression. Specifi-
cally, issues around poor self-perception about having
HIV, and the implications of disclosure,may be addressed
through interventions to support young people’s adjust-
ment to HIV, including peer-based, residential, and in-
dividual therapy approaches. In terms of specific ART
drugs, our study was conducted in the preintegrase
inhibitor era, and newer ART strategies have a higher
genetic barrier to drug resistance, and together with long-
acting injectables provide novel improved options for
young people with PHIV for the future. Individualized
transition programs with appropriate support may be re-
quired to help maintain optimal medication adherence in
this group (Kowalska et al., 2019). Thus, individualizing
medication to address varied challenges is important for
young people transitioning to adult care and to enable
them to achieve optimal health in adulthood.
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